Long-term follow-up of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer reveals relapse characterized by immune exhaustion.

Mikayla Borthwick Bowen Brenda D Melendez Qian Zhang Richard K Yang Bryan M Fellman Barrett C Lawson Naomi N Adjei Joseph Celestino Khalida M Wani Bhavana Singh Diana L Urbauer Alexander J F Lazar Karen H Lu Jennifer A Wargo Shannon Neville Westin Melinda S Yates

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Upfront resistance and relapse after initial response to LIUD for AH/G1EEC impacts nearly half of patients, remaining a major hurdle for non-surgical treatment of AH/G1EEC. Molecular studies evaluating longitudinal biopsies from a small cohort implicate immune mechanisms at relapse, including reversal of progestin-related immunomodulation and increased immune exhaustion.

Keyphrases

endometrial cancer
end stage renal disease
free survival
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
ultrasound guided
patient reported
drug induced